ArticleInternational urology and nephrology2026
Quantitative synthetic MRI improves peripheral zone prostate cancer detection beyond PI-RADS v2.1.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Turning end-of-surgery AKI risk into actionable care: a call for thresholded, calibrated deployment.International urology and nephrology · 2026Article
- Concerns on the generalizability of a CSA-AKI prediction model: the dual challenges of disparate event rates and divergent data generating processes.International urology and nephrology · 2026Article
- Key considerations of explainable machine learning models for the early forecasting of acute kidney injury following cardiac surgery.International urology and nephrology · 2026Article
- Machine learning in early prediction of acute kidney injury: model reliability, clinical applicability, and generalizability.International urology and nephrology · 2026Article
- Turning AKI risk into action with calibrated, transport-tested machine learning.International urology and nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAccurate diagnosis of peripheral zone prostate cancer is challenging. The Prostate Imaging-Reporting and Data System (PI-RADS v2.1) is widely used but remains subjective and often requires contrast agents. Synthetic MRI (SyMRI) generates quantitative T1 and T2 relaxation maps rapidly and without contrast. This study assessed the diagnostic performance of SyMRI compared with PI-RADS v2.1.
methodsIn this retrospective single-center study, 70 men with suspected prostate cancer underwent both multi-parametric MRI and SyMRI, followed by histopathological confirmation. Quantitative T1, T2, and proton density values were extracted from SyMRI, and two radiologists independently assigned PI-RADS v2.1 scores. Diagnostic accuracy was evaluated using ROC analysis with pathology as the reference standard.
resultsMalignant lesions showed significantly reduced T1 (median 1230 ms vs. 1997 ms, p < 0.01) and T2 values (79 ms vs. 132 ms, p < 0.01) compared with benign lesions, while proton density was not different. Optimal thresholds of 1495 ms (T1) and 90.6 ms (T2) achieved sensitivities of 92.5% and specificities of 80.0% and 90.0%, respectively. AUC values were 0.868 for T1, 0.952 for T2, and 0.663 for PI-RADS alone. The combined use of T1, T2, and PI-RADS yielded the highest diagnostic accuracy (AUC = 0.993).
conclusionQuantitative SyMRI provides reproducible, contrast-free biomarkers that significantly enhance detection of peripheral zone prostate cancer beyond PI-RADS v2.1. Incorporating T1 and T2 mapping into clinical MRI protocols may improve early diagnosis, reduce dependence on contrast agents, and potentially lower unnecessary biopsy rates. Given the modest sample size and the absence of a priori power analysis, these findings should be interpreted as exploratory and validated in larger, prospective cohorts.
Indexed as
Identifiers
41286239What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.